---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210664"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:56:40.128499+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aardvark Q1 net loss $21.6M; ARD-101/ARD-201 programs on voluntary pause

## Summary
- Net loss of $21.6M for Q1 2026 vs. $9.3M for Q1 2025, driven by higher R&D expenses.
- Cash, cash equivalents and ST investments at $91.2M (down from $110.0M Dec 31, 2025); runway into mid-2027.
- R&D expenses $16.6M (up $8.8M YoY) due to ARD-101 development and personnel costs.
- Voluntary pause on Phase 3 HERO trial and ARD-201 after reversible cardiac signals in a healthy volunteer study.
- Company working with FDA and expects to provide program guidance in Q2 2026.

## SEC filing metadata
- accession: 0001193125-26-210664
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/ck0001774857-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210664
- JSON: https://secwatch.observer/filing/0001193125-26-210664.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210664.txt

## Source-grounded claims
- claim_id: e0a0c8d29575bd0ef2b7d2d438a802f32e741e86
  claim: Aardvark Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $91.2 million, net income net loss of $21.6 million.
  evidence_excerpt: Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark
  evidence_url: https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.